Table 3 Univariate regression and multivariate survival model of prognostic covariates in patients with glioma
Characteristics | Total (N) | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|---|
HR(95% CI) | P | HR(95% CI) | P | ||
WHO grade (WHO-IV vs. WHO-II&III) | 612 | 9.504 (7.162–12.611) |  < 0.001 | 3.317 (0.958–11.487) | 0.059 |
IDH status (WT vs. Mut) | 660 | 9.850 (7.428–13.061) |  < 0.001 | 3.907 (2.181–6.998) |  < 0.001 |
1p/19q co-deletion (codel vs. non-codel) | 663 | 0.216 (0.138–0.338) |  < 0.001 | 0.736 (0.413–1.313) | 0.3 |
Primary therapy outcome (CR vs. PD&SD&PR) | 443 | 0.238 (0.115–0.489) |  < 0.001 | 0.335 (0.152–0.736) | 0.006 |
Gender (Male vs. Female) | 669 | 1.230 (0.955–1.585) | 0.109 |  |  |
Age (> 60 vs. <  = 60) | 669 | 4.716 (3.609–6.161) |  < 0.001 | 3.558 (2.115–5.984) |  < 0.001 |
Race (White vs. Asian&Black or African American) | 657 | 0.806 (0.492–1.321) | 0.393 |  |  |
EGFR status (Mut vs. WT) | 655 | 3.628 (2.672–4.927) |  < 0.001 | 1.606 (0.763–3.379) | 0.212 |
PIK3CA status (Mut vs. WT) | 655 | 1.011 (0.625–1.635) | 0.966 |  |  |
SIRPB1 (High vs. Low) | 669 | 3.003 (2.294–3.932) |  < 0.001 | 2.203 (1.415–3.429) |  < 0.001 |